- Home
- TOPS vs KPTI Comparison
TOPS vs KPTI Comparison
Compare TOPS & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TOPS
- KPTI
- Stock Information
- Founded
- TOPS 2000
- KPTI 2008
- Country
- TOPS Greece
- KPTI United States
- Employees
- TOPS N/A
- KPTI N/A
- Industry
- TOPS Marine Transportation
- KPTI Biotechnology: Pharmaceutical Preparations
- Sector
- TOPS Consumer Discretionary
- KPTI Health Care
- Exchange
- TOPS Nasdaq
- KPTI Nasdaq
- Market Cap
- TOPS 28.3M
- KPTI 29.8M
- IPO Year
- TOPS 2004
- KPTI 2013
- Fundamental
- Price
- TOPS $5.88
- KPTI $3.73
- Analyst Decision
- TOPS
- KPTI Strong Buy
- Analyst Count
- TOPS 0
- KPTI 5
- Target Price
- TOPS N/A
- KPTI $61.00
- AVG Volume (30 Days)
- TOPS 9.0K
- KPTI 147.0K
- Earning Date
- TOPS 04-15-2025
- KPTI 05-07-2025
- Dividend Yield
- TOPS N/A
- KPTI N/A
- EPS Growth
- TOPS N/A
- KPTI N/A
- EPS
- TOPS N/A
- KPTI N/A
- Revenue
- TOPS $83,870,000.00
- KPTI $145,237,000.00
- Revenue This Year
- TOPS $7.10
- KPTI $4.87
- Revenue Next Year
- TOPS $6.54
- KPTI $16.29
- P/E Ratio
- TOPS N/A
- KPTI N/A
- Revenue Growth
- TOPS 1.10
- KPTI N/A
- 52 Week Low
- TOPS $5.30
- KPTI $3.51
- 52 Week High
- TOPS $14.24
- KPTI $21.60
- Technical
- Relative Strength Index (RSI)
- TOPS 40.39
- KPTI 28.96
- Support Level
- TOPS $6.33
- KPTI $3.51
- Resistance Level
- TOPS $6.55
- KPTI $4.09
- Average True Range (ATR)
- TOPS 0.20
- KPTI 0.57
- MACD
- TOPS -0.01
- KPTI -0.10
- Stochastic Oscillator
- TOPS 12.73
- KPTI 8.18
About TOPS TOP Ships Inc.
TOP Ships Inc owns tanker vessels throughout the world. The company focuses on the transportation of petroleum products (clean and dirty) and bulk liquid chemicals. The Company is an international provider of worldwide oil, petroleum products and chemical transportation services. It generates revenue from the Time Charter agreements.
About KPTI Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.